Molecular targets on the horizon for kidney and urothelial cancer (Q38132039)

29 August 2017

Molecular targets on the horizon for kidney and urothelial cancer (English)

1 reference

29 August 2017

Jonathan E Rosenberg

4

0 references

Giampaolo Tortora

object named as

Giampaolo Tortora

series ordinal

3

0 references

Bin Tean Teh

object named as

Bin T Teh

series ordinal

2

0 references

author name string

Joaquim Bellmunt

series ordinal

1

1 reference

PubMed ID

23982523

29 August 2017

language of work or name

English

0 references

publication date

27 August 2013

1 reference

Nature Reviews Clinical Oncology

29 August 2017

1 reference

29 August 2017

10

1 reference

29 August 2017

10

1 reference

29 August 2017

557-570

1 reference

29 August 2017

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Clonal origin of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

von Hippel-Lindau disease: a clinical and scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Inhibition of mTORC2 but not mTORC1 up-regulates E-cadherin expression and inhibits cell motility by blocking HIF-2α expression in human renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

BAP1 loss defines a new class of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

The SWI/SNF complex and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Comprehensive molecular characterization of clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Hereditary leiomyomatosis and renal cell cancer: an unusual and aggressive form of hereditary renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Hypermethylation of the 5'CpG island of the FHIT gene in clear cell renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Treatment selection in metastatic renal cell carcinoma: expert consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Renal toxicity of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

The genetic basis of kidney cancer: a metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Economic aspects of bladder cancer: what are the benefits and costs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

New therapeutic challenges in advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Applications of array technology: identification of molecular targets in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

A molecular taxonomy for urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Phase II study of everolimus in metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

RETRACTED ARTICLE. Localized synovial hypertrophy in the anteromedial compartment of the osteoarthritic knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Fibroblast growth factor receptor-3 in urothelial tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Oncogenic FGFR3 gene fusions in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

mTOR signaling pathway and mTOR inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

TSC1 involvement in bladder cancer: diverse effects and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Phase II study of sunitinib in patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Hsp27 protects adenocarcinoma cells from UV-induced apoptosis by Akt and p21-dependent pathways of survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

On the role of Hsp27 in regulating apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Hsp27 negatively regulates cell death by interacting with cytochrome c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Breast cancer survivors and hot flashes: the search for nonhormonal treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion - the prognostic contribution of related molecular markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

The Chromatin Remodeling Gene ARID1A Is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Targeting p53 for Novel Anticancer Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

The FGFR3 mutation is related to favorable pT1 bladder cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.155

Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

31 March 2020

1 reference

12 December 2020

Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.

1 reference

12 December 2020

Pathology of renal cell carcinoma: an update

1 reference

12 December 2020

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice

1 reference

12 December 2020

Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma

1 reference

12 December 2020

EGF, TGF alpha, AR and HB-EGF are autocrine growth factors for human bladder carcinoma cell lines

1 reference

12 December 2020

Methylation-associated silencing of TU3A in human cancers

1 reference

12 December 2020

Loss of 14q31-q32.2 in renal cell carcinoma is associated with high malignancy grade and poor survival

1 reference

12 December 2020

Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors.

1 reference

12 December 2020

Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer

1 reference

12 December 2020

Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma

1 reference

12 December 2020

Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.

1 reference

12 December 2020

10.1038/NRCLINONC.2013.155

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23982523